Peak inspiratory flow through the Genuair® inhaler in patients with moderate or severe COPD  by Magnussen, H. et al.
Respiratory Medicine (2009) 103, 1832e1837ava i lab le a t www.sc iencedi rec t .com
journa l homepage : www.e lsev ie r . com/ loca te / rmedPeak inspiratory flow through the Genuair inhaler
in patients with moderate or severe COPDH. Magnussen a,*, H. Watz a, I. Zimmermann a, S. Macht a, R. Greguletz b,
M. Falques c, D. Jarreta c, E. Garcia Gil ca Pulmonary Research Institute, Hospital Grosshansdorf, Center for Pneumology and Thoracic Surgery,
Woehrendamm 80, 22927 Grosshansdorf, Germany
b Almirall Sofotec GmbH, Benzstrasse 1, D-61352 Bad Homburg v. d. Hoehe, Germany
c Almirall, R&D Centre, Laurea` Miro´ 408-410, 08980 Sant Feliu de Llobregat, Barcelona, Spain
Received 13 February 2009; accepted 13 July 2009
Available online 3 August 2009KEYWORDS
Chronic obstructive
pulmonary disease;
Dry powder inhaler;
Genuair inhaler;
Peak inspiratory flow* Corresponding author. Tel.: þ
4102601245.
E-mail address: magnussen@pulmo
0954-6111/$ - see front matter ª 200
doi:10.1016/j.rmed.2009.07.006Summary
The Genuair inhaler is a new multidose dry powder inhaler for the delivery of aclidinium
bromide e a novel, long-acting, muscarinic antagonist in development for the treatment of
chronic obstructive pulmonary disease (COPD). The primary aim of this study was to assess
the inspiratory flow characteristics through Genuair in patients with moderate or severe
COPD.
Using a three-period cross-over design, 48 patients were randomised to inhale placebo
powder through Genuair, HandiHaler A (slow, deep inhalation as per manufacturer’s instruc-
tions) or HandiHaler B (fast, forceful inhalation). Three measurements of peak inspiratory
flow (PIF), 10 min apart, were recorded for each method of administration.
The highest and average PIFs for the three attempts (mean standard deviation) generated
through the Genuair inhaler were 97.7 15.7 and 92.0 15.4 L/min, respectively. Further-
more, 97% of inhalations with the Genuair inhaler were successful (activation of trigger
threshold mechanism) and optimal (PIF 45 L/min). The highest and average PIFs generated
through HandiHaler A and B were significantly lower than with the Genuair inhaler.
In conclusion, patients with moderate or severe COPD were able to generate sufficient inspi-
ratory airflow through the Genuair inhaler to reliably inhale the full dose and reset the
inhaler.
ª 2009 Published by Elsevier Ltd.49 4102601151; fax: þ49
research.de (H. Magnussen).
9 Published by Elsevier Ltd.Introduction
Unlike pressurised metered-dose inhalers, dry powder
inhalers (DPIs) do not require patients to coordinate
Inspiratory flow through the Genuair inhaler 1833actuationwith inhalation and are propellant-free. As a result
of these advantages, DPIs are replacing pressurisedmetered-
dose inhalers in the management of patients with chronic
obstructive pulmonary disease (COPD).1 When using a DPI,
patients are required to generate sufficient inspiratory flow
to deagglomerate the powder into smaller particles for
delivery to the airways.2,3 The inspiratory flow achieved by
patients is dependent partly on their inspiratory effort and
partly on the airflow resistance of the inhaler.4 Patientsmust
invest a greater inspiratory effort to achieve the same
inspiratory flow through a high-resistance inhaler compared
with a low-resistance inhaler. Some patients with COPD may
have problems generating sufficient inspiratory flow through
a high-resistance inhaler.4,5 Therefore, when developing
a new inhaler for the delivery of COPD medication, it is
important to establish whether the target population can
achieve an adequate inspiratory flow through the inhaler.
The Genuair inhaler (Fig. 1) is a new breath-actuated,
multidose DPI for the delivery of aclidinium bromide, a novel,
long-acting, muscarinic antagonist in development for the
treatment of COPD. This inhaler has been designed to
provide:multi-sensory feedback to the patient that a dosehas
been taken correctly; a trigger threshold function to prevent
accidental double-dosing; and a lock-out mechanism that
prevents furtheruse of the inhaler after the last dosehas been
taken. The Genuair inhaler contains 1 month of therapy,
requires no cleaning, and is disposable after all the doses have
been delivered. A dose indicator tracks the doses, with a red
strip appearing when the patient is close to the last dose.
This study assessed the inspiratory flow characteristics
of the Genuair inhaler in patients with moderate or severe
COPD. For comparison, an exploratory investigation of
inspiratory flow through the HandiHaler, a single-dose DPI,
was performed in the same patient population.
Methods
Study design
This was an open-label, randomised, cross-over study con-
ducted at a single centre in Germany to assess theProtective cap
Dose indicator
Mouthpiece
Control window
Button
Figure 1 The Genuair inhaler.inspiratory flow characteristics of the Genuair inhaler.
Eligible patients were enrolled within 7 days of the
screening visit. Patients were trained in the correct use of
the Genuair inhaler and the HandiHaler by written and
verbal instruction. The steps required to use the Genuair
inhaler and the HandiHaler are briefly described below.
For a correct inhalation through the Genuair inhaler,
the patient must first remove the protective mouthpiece
cap, then press and release the button on top of the inhaler
to load a single dose into the powder inhalation chamber.
The control window will simultaneously change from red to
green to indicate that the inhaler is ready to use. The
patient must then inhale through the mouthpiece to release
the dose. Successful inhalation is indicated by an audible
click, a slightly sweet taste that may be perceived by some
patients, and the control window changing from green to
red. In addition, once the button has been pressed and
released, there is a ‘trigger threshold’ feature that
prevents another dose from being loaded until after
successful inhalation has occurred.
For a correct inhalation through the HandiHaler, the
patient first must remove a capsule containing a single dose
of medication from a package, open the mouthpiece of the
inhaler and place the capsule in the centre chamber. After
closing the mouthpiece, the patient must press a side
button to pierce the capsule. The patient then inhales
through the mouthpiece to deliver the medication. Finally,
the mouthpiece is opened again and the used capsule is
discarded. Confirmation of dose delivery is provided by
hearing the capsule vibrate, tasting the powder and seeing
the empty capsule.
When using the Genuair inhaler, patients were asked to
inhale as fast and hard as possible. Inhalations through the
HandiHaler were performed according to two different
instructions: inhalation by a slow, deep breath, but at
a rate rapid enough to hear the capsule vibrate, as per the
manufacturer’s instructions (HandiHaler A), or inhalation
as fast and hard as possible, simulating the instructions for
use of the Genuair inhaler (HandiHaler B). Patients
inhaled placebo powder through the three inhalers (Gen-
uair inhaler, HandiHaler A and HandiHaler B) in
a random order (six different sequences). For each inha-
ler, three measurements per patient were recorded at
10-minute intervals. During inhalation manoeuvres, the
inhalers were connected to a spirometer through specially
designed airtight adaptors.
The study was conducted in accordance with the
Declaration of Helsinki, Principles for Correct Imple-
mentation of Clinical Trials, and International Conference
on Harmonisation Good Clinical Practice Guidelines. An
independent Ethics Committee approved the study and all
patients provided written informed consent.Patients
Male and non-pregnant female patients aged 40 yrs were
eligible to enter the study if they had a diagnosis ofmoderate
or severeCOPDand stable airwayobstruction.6 Patientswere
required to have a post-salbutamol forced expiratory volume
in 1 s (FEV1)/forced vital capacity (FVC) of <70% at
screening. Half of the patients were required to have
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Figure 2 In vitro assessments of the fine particle dose <5 mm
at various flow rates for the Genuair inhaler (Almirall, data on
file 2009) and the Handihaler.11 Minimum average PIFs ach-
ieved in our clinical study are also indicated.
Table 1 Demographic and baseline characteristics by
disease severity.
Moderate COPD
(nZ 24)
Severe COPD
(nZ 24)
Age yrs 63 (8.0) 65 (6.7)
Male 18 (75) 18 (75)
Caucasian 24 (100) 24 (100)
BMI kg/m2 28.0 (5.2) 29.2 (6.7)
Duration of COPD yrs 8.3 (9.5) 11.6 (8.2)
Current smoker 15 (62.5) 11 (45.8)
Smoking history pack-yrs 61.5 (25.7) 55.0 (24.3)
Post-salbutamol FEV1 %
of predicted value
59.5 (6.9) 40.9 (5.9)
Post-salbutamol FVC L 3.78 (1.23) 3.27 (0.79)
Post-salbutamol FEV1/FVC
ratio %
47.8 (9.5) 37.7 (8.9)
Salbutamol test %
reversibility
19.3 (15.1) 19.0 (15.1)
Prior use of Novolizer 4 (16.7) 9 (37.5)
Prior use of Handihaler 17 (70.8) 21 (87.5)
Data are presented as n (%) or mean (SD) unless otherwise
indicated.
BMI, body mass index; COPD, chronic obstructive pulmonary
disease; FEV1, forced expiratory volume in 1 s; FVC, forced vital
capacity; SD, standard deviation.
1834 H. Magnussen et al.moderate COPD, as defined by a post-salbutamol FEV1 50%
and <80% of the predicted value, while the remaining
patients were required to have severe COPD, as defined by
a post-salbutamol FEV1 30% and <50% of the predicted
value. All patients were current or previous cigarette
smokers with a smoking history of at least 10 pack-yrs.
Patients were excluded for any of the following reasons:
history or current diagnosis of asthma, allergic rhinitis or
atopy; respiratory tract infection or COPD exacerbation
within 6 weeks of the screening visit; hospitalisation for
acute COPD exacerbation within 3 months of the screening
visit; use of long-term oxygen therapy (15 h/day); clini-
cally significant respiratory conditions other than those
related to the inclusion criteria; clinically significant
cardiovascular conditions; clinically relevant medical find-
ings or abnormalities unrelated to COPD; lactose intoler-
ance; treatment with any investigational medical product
within 1 month of screening.
The use of long-acting anticholinergic agents, long-acting
inhaled b2-agonists and sustained-release theophylline was
prohibited for at least 72, 48 and 24 h, respectively, before
the screening visit and study entry. Salbutamol was
permitted as rescue medication during the washout period,
but had to be discontinued at least 6 h before the screening
visit and study entry.
Objectives
The primary objective of the study was to determine the
peak inspiratory flow (PIF) generated through the Genuair
inhaler by patients withmoderate or severe COPD. Secondary
objectives were to determine the rate of successful and/or
optimal inhalations with the Genuair inhaler and the PIF
generated through the HandiHaler A and B.
Inhaler evaluation
PIF was measured using standard spirometry. Successful
inhalation through the Genuair inhaler was defined as an
inhalation sufficient to activate the inhaler trigger and
produce a colour change from green to red in the control
window. Optimal inhalation through the Genuair inhaler
was defined as an inhalation that produced a PIF 45 L/
min, to ensure full dose inhalation based on unpublished in
vitro data showing a constant fine particle dose between
the flow rates of 45 and 95 L/min (Almirall, data on file
2009; Fig. 2). For each inhalation through the HandiHaler
A, capsule vibration heard by the investigator and powder
remaining in the centre chamber of the inhaler were
recorded (these endpoints were not assessed for Handi-
Haler B).
Statistical analyses
All variables were summarised by means of appropriate
descriptive statistics and were tabulated by inhaler group
(Genuair inhaler, HandiHaler A and HandiHaler B) for all
patientsandbyCOPD severity. Thehighest andaveragePIFs of
the three attempts were assessed by an analysis of variance
model for cross-over designs, with period, sequence, patient
within sequence and inhaler as effect variables.Results
Patients
A total of 48 patients with moderate (nZ 24) or severe
(nZ 24) COPD were randomised and completed the study.
Demographic and baseline characteristics of the study
population are shown in Table 1.
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In the overall population, the highest and average PIFs of
the three attempts (mean standard deviation [SD])
generated through the Genuair inhaler were 97.7 15.7 L/
min (Fig. 3) and 92.0 15.4 L/min, respectively.
The highest PIFs (mean SD) of the three attempts
generated through HandiHaler A and HandiHaler B in the
overall population were 51.2 10.4 and 64.3 8.7 L/min,
respectively; these values were significantly lower than the
highest PIF for the Genuair inhaler in the same population
(P< 0.001; Fig. 3). Similarly, the average PIFs of the three
attempts generated through HandiHaler A (46.1 9.6 L/
min) and HandiHaler B (61.5 8.9 L/min) were also
significantly lower than for the Genuair inhaler (P< 0.001).
When patients were stratified by disease severity, the
highest PIFs (Fig. 3) and average PIFs were slightly greater
for patients with moderate COPD compared with those with
severe COPD for the Genuair inhaler (9% and 7% differ-
ence, respectively), HandiHaler A (3% difference for both)
and HandiHaler B (5% difference for both).
Individual patient data for the highest PIF of the three
attempts for the Genuair inhaler compared with Handi-
Haler A and B are presented in Fig. 4a and b, respectively.
These data show that patients consistently achieved
a greater PIF when using the Genuair inhaler compared
with Handihaler A or B.
Evaluation of correct inhalation
Successful and optimal inhalations with the Genuair
inhaler
Overall, 97.2% (140/144) of inhalations with the Genuair
inhaler were successful and optimal. One patient with
moderate COPD had an unsuccessful and suboptimal inha-
lation at the first attempt, with a PIF of 43.8 L/min. This
patient successfully and optimally inhaled through the
Genuair inhaler on the second and third attempts,H
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Figure 3 Mean (SD) highest peak inspiratory flow (PIF) with
each inhaler in the overall population and by disease severity.
COPD, chronic obstructive pulmonary disease; SD, standard
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Figure 4 Scatter plot showing individual patient data for
highest peak inspiratory flow (PIF) of the three attempts for
the Genuair inhaler compared with (a) HandiHaler A and (b)
HandiHaler B. COPD, chronic obstructive pulmonary disease.achieving PIFs of 58.8 and 61.2 L/min, respectively. For one
patient with severe COPD, all three attempts were optimal
but unsuccessful, despite generating PIFs between 61.8 and
91.8 L/min.
Capsule vibration and residual powder with HandiHaler A
Capsule vibration and residual powder data for Handi-
Haler A are shown in Table 2. The investigator heard
Table 2 Capsule vibration and residual powder data per inhalation for HandiHaler A in the overall population.
Residual powder in centre chamber No residual powder in centre chamber Total
Capsule vibration heard 11/144 (7.6) 106/144 (73.6) 117/144 (81.3)
No capsule vibration heard 20/144 (13.9) 7/144 (4.9) 27/144 (18.8)
Total 31/144 (21.5) 113/144 (78.5) 144/144 (100)
Data are presented as n/N (%).
1836 H. Magnussen et al.capsule vibration after 81.3% (117/144) of the inhalations
and no powder remained in the centre chamber after
78.5% (113/144) of the inhalations. No capsule vibration
was heard and some powder remained in the centre
chamber for 13.9% (20/144) of the inhalations.Discussion
The PIF generated through the Genuair inhaler by patients
with moderate or severe COPD was significantly greater
than that generated through the HandiHaler, irrespective
of whether patients inhaled through the HandiHaler using
a slow, deep breath (according to the manufacturer’s
instructions) or using a fast, forceful breath, as for the
Genuair inhaler. PIF has been shown to be inversely
proportional to the intrinsic resistance of an inhaler.7
Therefore, the results from this study confirm that the
Genuair inhaler has a lower flow resistance than the
HandiHaler, which translates to a lower inspiratory effort
needed to produce a comparable PIF. The lower flow
resistance associated with the Genuair inhaler may
benefit patients with COPD, particularly those with low
inhalation capacity. Patients with moderate or severe COPD
often have difficulty achieving sufficient inspiratory flow
through DPIs with high resistance.4 Furthermore, the ability
to generate sufficient inspiratory flow through a DPI
appears to be compromised in elderly (>70 yrs) patients,5
which is of particular relevance since elderly patients
account for a considerable proportion of patients with
COPD.8,9 Therefore, the use of an inhaler with low to
medium resistance, leading to achievable flow rates of
typically 60e90 L/min,10 may be important in facilitating
effective drug inhalation in patients with COPD.
Patients with moderate COPD are expected to be able to
generate a higher PIF than those with severe COPD, and this
difference is likely to be more obvious with a lower-resis-
tance inhaler. Therefore, the slightly greater increases in
highest and average PIF for patients with moderate vs.
severe COPD for the Genuair inhaler vs. the HandiHaler
are consistent with the Genuair inhaler having lower flow
resistance than the HandiHaler.
The PIF associated with the HandiHaler in this study
was slightly greater than that reported in a previous study
of the inhaler in patients with moderate or severe COPD,
where the highest and median PIFs were 45.6 and 30.0 L/
min, respectively.11 This may reflect the fact that patients
in the previous study had more severe lung obstruction
(FEV1 16e65% of the predicted value) and were older (mean
age 66.9 yrs) than patients in this study.
A high proportion (97.2%) of patients achieved optimal
and successful inhalations through the Genuair inhaler,confirming that the inhaler ensures reliable delivery with no
risk of accidental double/multiple dosing. For the one
attempt where the PIF generated was <45 L/min, the
control window did not change colour from green to red.
Therefore, in a real-life situation, the patient would have
seen clearly that the inhalation was not optimal and should
have inhaled again.
In contrast, approximately one-quarter of inhalations
through HandiHaler A were performed incorrectly
according to study criteria. A previous study of the Handi-
Haler has shown that flow rates above 28.3 L/min are
required for a consistent fine particle dose (Fig. 2).11
However, the lowest average PIF generated through Hand-
iHaler A by patients with severe COPD was 24.0 L/min,
a flow rate at which insufficient dosing to the patient may
occur (Fig. 2).11 By comparison, all patients inhaling
through the Genuair inhaler achieved an average PIF
above that required in vitro for a consistent fine particle
dose (Fig. 2).11 It must be noted that according to the
manufacturer’s instructions, the patient should inhale
twice through the HandiHaler in order to empty the
capsule completely, whereas the data presented in this
study are for single inhalations through the HandiHaler
because the aim was to measure PIF. As there was some
remaining powder in the centre chamber for almost
a quarter (21.5%) of the single inhalations through the
HandiHaler in this study, these data support the require-
ment for two inhalations with the HandiHaler.
A gamma scintigraphic study has assessed the lung
deposition of a single dose of radiolabelled aclidinium
200 mg administered from the Genuair inhaler at a mean
(SD) PIF of 79 (9) L/min in 12 healthy males.12 The results
showed that the Genuair inhaler delivered aclidinium
efficiently, with approximately 30% of the metered dose
deposited in the lungs. Furthermore, lung deposition was
consistent across the PIF range of 66e99 L/min. In a similar
gamma scintigraphic study of radiolabelled tiotropium
administered from the HandiHaler in five healthy subjects
and 15 patients with COPD, the lung deposition of tio-
tropium was approximately 20%, regardless of the presence
or severity of COPD.13
In conclusion, results from this study demonstrate that
patients with moderate or severe COPD can achieve suffi-
cient inspiratory airflow through the Genuair inhaler to
reliably inhale the full dose and reset the inhaler.Acknowledgements
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